Completed
Thioctic Acid and Deprenyl for HIV Dementia Treatment
What is being tested
Thioctic acid
+ Selegiline hydrochloride
Drug
Who is being recruted
Blood-Borne Infections+18
+ Urogenital Diseases
+ Genital Diseases
Over 18 Years
+16 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 2
Interventional
Summary
Principal SponsorThe Dana Foundation
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Patients are randomized to receive thioctic acid alone, deprenyl alone, thioctic acid/deprenyl, or placebo alone for 10 weeks, after which all patients may receive active drug on an open-label basis. Patients must have seven clinic visits.
Principal SponsorThe Dana Foundation
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
32 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesMental DisordersCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsNeurocognitive DisordersAcquired Immunodeficiency SyndromeAIDS-Related ComplexCognition DisordersHIV InfectionsCognitive Dysfunction
Criteria
7 inclusion criteria required to participate
Ability to give informed consent
Antiretrovirals provided dose has been stable for at least 6 weeks prior to study entry
HIV seropositivity
Mild to moderate cognitive impairment (problems with short term memory, concentration, and feeling slowed down)
Show More Criteria
9 exclusion criteria prevent from participating
Any other clinically significant condition or laboratory abnormality that would preclude participation on study
CNS neoplasms
Chemotherapy for malignancy
Current participation in other drug studies
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 3 locations
Columbia Univ
New York, United StatesUniv of Rochester Med Ctr
Rochester, United StatesCompleted3 Study Centers